4 January 2017 - If a decline in FDA approvals of new pharmaceuticals is a bad sign for the industry, then 2016 was the worst year since 2010.

And with only 18 FDA decisions on new drugs expected in 2017, according to BioPharma Catalyst, the number of FDA approvals may continue to decline to a level the industry has not seen since 2007, when 18 new molecular entities and new biologic license applications were approved.

Read Regulatory Affairs Professional Society blog